Status: Not yet recruiting
A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the Ability for the Antibodies to be Taken up by the Body Via the Colon
This is a proof-of-concept study to investigate whether antibodies (guselkumab and adalimumab) delivered directly to the colon can enter the systemic circulation. The study endpoints chosen for this study are commonly used for evaluating the safety, tolerability, and PK of single doses of IPs. No interim analysis is planned.
Participants needed: 18
Trial details
Phase: Phase 1Age: 18-45Biological sex: AllType: InterventionalSponsor: Surmount Services, Inc.Updated: Aug 26, 2026
Eligibility criteria
In good general health, with no significant medical history, and have no clinica... [+1]
Pregnant, planning to become pregnant, or currently breastfeeding [+3]